1. Home
  2. AGIO vs PAX Comparison

AGIO vs PAX Comparison

Compare AGIO & PAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

N/A

Current Price

$30.98

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Logo Patria Investments Limited

PAX

Patria Investments Limited

N/A

Current Price

$9.53

Market Cap

1.8B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
AGIO
PAX
Founded
2007
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.8B
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
AGIO
PAX
Price
$30.98
$9.53
Analyst Decision
Buy
Buy
Analyst Count
10
6
Target Price
★ $46.11
$14.83
AVG Volume (30 Days)
1.2M
★ 1.6M
Earning Date
11-05-2026
11-03-2026
Dividend Yield
N/A
★ 6.71%
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $43,011,000.00
N/A
Revenue This Year
$227.92
$14.94
Revenue Next Year
$96.10
$6.21
P/E Ratio
★ N/A
$25.65
Revenue Growth
N/A
N/A
52 Week Low
$22.24
$9.03
52 Week High
$46.00
$17.80

Technical Indicators

Market Signals
Indicator
AGIO
PAX
Relative Strength Index (RSI) 44.24 37.80
Support Level $26.41 $9.03
Resistance Level $35.77 $11.74
Average True Range (ATR) 1.85 0.40
MACD -0.54 -0.07
Stochastic Oscillator 30.47 16.56

Price Performance

Historical Comparison
AGIO
PAX

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

About PAX Patria Investments Limited

Patria Investments Ltd is an alternative asset management firm specializing in resilient sectors across select regions. It seeks to provide world-wide and Latin American investors with attractive investment products that allows portfolio diversification and consistent returns. The group promotes inclusive and sustainable development in the Asset Classes: Private Equity, Private Equity Solutions, Credit, Real Estate, Infrastructure, and Public Equities Main sectors: Agribusiness, Power & Energy, Healthcare, Logistics & Transportations, Food & Beverage and Digital & Tech Services Investment Regions.

Share on Social Networks: